Pharma BD Deal Intelligence
Roche's 2011 acquisition of mtm laboratories delivered on the CINtec cervical-cancer testing thesis—but slowly: FDA approval didn't land until 2020, and global standard-of-care status (WHO guideline endorsement) came only in 2024, 13 years after the $269M deal closed. Roche has never disclosed CINtec as a standalone revenue line, leaving the win real but financially unverifiable.
Took 9 years to reach the US market and 13 to become the global standard of care, but CINtec ultimately delivered on the cervical-cancer-testing thesis — just never as a disclosed, scaled revenue line.
Full analysis, sources & comparables →mtm products are highly complementary to Roche's innovative cobas HPV assay, creating a comprehensive cervical cancer testing portfolio from cytological…
Roche acquires mtm laboratories, broadening cervical cancer testing capabilities; mtm products are highly complementary to Roche's cobas HPV assay, giving a…
Roche extends cervical cancer diagnostics franchise via €190M acquisition of mtm laboratories, gaining p16 biomarker IP that complements its molecular HPV…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Roche/Ventana acquired German cervical-cancer diagnostics specialist mtm laboratories for €130M upfront (~$184M) plus up to €60M (~$85M) in milestones; total up to ~$269M. Complemented Roche's cobas HPV cervical screening platform.
Took 9 years to reach the US market and 13 to become the global standard of care, but CINtec ultimately delivered on the cervical-cancer-testing thesis — just never as a disclosed, scaled revenue line.
Assessment window: 10yr post-close.
12K US cases/yr
Cervical cancer is a malignancy of the cervix typically caused by persistent infection with high-risk human papillomavirus (HPV). Screening with cytology (Pap) and HPV testing detects pre-cancerous lesions (CIN) early, enabling treatment before progression to invasive disease. Despite screening, ~12,000-13,000 new US cases occur annually, with disparities concentrated among under-screened populations.
Cervical cancer screening in 2011 was anchored by cytology (Pap) and high-risk HPV DNA testing. Roche's cobas HPV test competed with Qiagen/Digene's Hybrid Capture 2 (HC2) — long the market standard — and Abbott's RealTime HR HPV assay. The mtm laboratories acquisition added p16 INK4a-based biomarker assays (CINtec Histology and CINtec PLUS Cytology), which detect oncogenic HPV-driven cell-cycle dysregulation rather than viral DNA itself. This positioned Roche to layer a triage/confirmatory biomarker on top of its cobas 4800 HPV platform — addressing the well-known specificity gap of HPV DNA testing (positive but transient infections) and reducing unnecessary colposcopy referrals. Competitors at the time lacked an integrated p16 dual-stain offering. The deal made Roche the only player with HPV primary screening + p16/Ki-67 dual-stain triage + reflex cytology under one diagnostics roof, deepening its lead over Hologic, BD (TriPath), and Abbott in women's health diagnostics.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / mtm laboratories AG (this deal) | 2011 | $269M | 65 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2011 deals · Roche Holding AG deals · Oncology deals